HIGH-DOSE INTRAPERITONEAL APROTININ TREATMENT OF ACUTE SEVERE PANCREATITIS - A DOUBLE-BLIND RANDOMIZED MULTICENTER TRIAL

被引：22

作者：

BERLING, R

GENELL, S

OHLSSON, K

机构：

[1] LUND UNIV,MALMO GEN HOSP,DEPT SURG PATHOPHYSIOL,S-21401 MALMO,SWEDEN

[2] LUND UNIV,MALMO GEN HOSP,DEPT ANAESTHESIOL,S-21401 MALMO,SWEDEN

来源：

JOURNAL OF GASTROENTEROLOGY | 1994年 / 29卷 / 04期

关键词：

ACUTE PANCREATITIS; APROTININ; TRASYLOL; PANCREATIC NECROSIS; PROTEASE INHIBITORS;

D O I：

10.1007/BF02361247

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

A multi-center double-blind trial was performed on 48 patients with severe acute pancreatitis. All patients were treated with intraperitoneal lavage. One group (n = 22) was also treated with high doses of the protease inhibitor, aprotinin (Trasylol; Bayer AG, Leverkusen, Germany) administered intraperitoneally. Eight patients died, giving a total mortality of 16.6%. No difference was observed between the two groups. Altogether, 12 patients were operated on, corresponding to 25%. In the group not treated with aprotinin, 6 patients were operated on because of pancreatic necrosis, compared with none in the treated group. The difference was statistically significant. There were no significant differences between the two groups with regard to organ failure or other complications. It was concluded that aprotinin counteracts the development of pancreatic necrosis when given intraperitoneally in high doses to patients with severe acute pancreatitis, thus reducing the need for surgical intervention in these patients.

引用

页码：479 / 485

页数：7

共 39 条

[1] Glazer G., Contentious issues in acute pancreatitis, Acute pancreatitis. Experimental and clinical aspects of pathogenesis and management, pp. 1-36, (1988)
[2] Chiari H., Über die Selbstverdaung des menshlichen Pankreas, Z Helik, 17, pp. 69-96, (1896)
[3] Geokas M.C., Rinderknecht H., Free proteolytic enzymes in pancreatic juice of patients with acute pancreatitis, Am J Dig Dis, 19, pp. 591-598, (1974)
[4] Rao K.N., Tuma J., Lombardi B., Acute hemorrhagic pancreatic necrosis in mice: Intraparenchymal activation of zymogens and other enzyme changes in pancreas and serum, Gastroenterology, 70, pp. 720-726, (1976)
[5] Yamaguchi H., Kimura T., Mimura K., Nawata H., Activation of proteases in cerulein-induced pancreatitis, Pancreas, 4, pp. 565-571, (1989)
[6] Ohlsson K., Olsson R., Bjork P., Et al., Local administration of human pancreatic secretory trypsin inhibitor prevents the development of experimental acute pancreatitis in rats and dogs, Scand J Gastroenterol, 24, pp. 693-704, (1989)
[7] Hirano T., Manabe T., Tobe T., Protection by gabexate mesilate (FOY) of the exocrine pancreas in rats with acute pancreatitis induced by a supramaximal dose of caerulein, J Gastroenterol Hepatol, 6, pp. 260-264, (1991)
[8] Fric P., Slaby J., Kasafirek E., Et al., Effective peritoneal therapy of acute pancreatitis in the rat with glutaryl-trialanin-ethylamide: A novel inhibitor of pancreatic elastase, Gut, 33, pp. 701-706, (1992)
[9] Trapnell J.E., Rigby C.C., Talbot C.H., Duncan E.H.L., A controlled trial of Trasylol in the treatment of acute pancreatitis, Br J Surg, 61, pp. 177-182, (1974)
[10] Iie C.W., Benjamin I.S., Ferguson J.C., Et al., A single-centre double-blind trial of Trasylol therapy in primary acute pancreatitis, Br J Surg, 65, pp. 337-341, (1978)

← 1 2 3 4 →